Compare Citius Pharmaceuticals Inc (CTXR) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Ulta Beauty Inc trades at $570.37 (market cap $24.12B). The key difference: Ulta Beauty Inc is far larger — about 1770.9× Citius Pharmaceuticals Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Ulta Beauty Inc for 92 Days on average.
| CTXR | ULTA | |
|---|---|---|
Market Cap | $13.62M | $24.12B |
Volume | 132,438 | 457,598 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $706.82 |
52-Week Low | $0.48 | $450.75 |
Typical Hold Time | 17 Days | 92 Days |
Enterprise Value | $3.79M | $26.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
ULTA stock trades at $570.37, up 4.56% today, reflecting strong momentum after recent earnings beats and raised 2026 guidance. The technical outlook is bullish, with the price near resistance at $572, while fundamentals show robust profitability with a 9.34% net margin and 46.12% ROE. Revenue growth is steady, reaching $11.3B in 2025, though margins face slight pressure. Analyst sentiment is positive, with a consensus price target of $624.93 and 59.57% buy ratings.
The stock presents a compelling growth opportunity supported by e-commerce acceleration and expansion into wellness categories, but risks include promotional pressures, flat store traffic, and margin compression. Execution on raised guidance and omnichannel strategy will be critical for sustaining the rally amid competitive and consumer spending headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
